Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
MEF2D is a member of the myocyte-specific enhancer factor 2 (MEF2) family of transcription factors. Additionally we are shipping MEF2D Antibodies (117) and MEF2D Proteins (6) and many more products for this protein.
Showing 1 out of 1 products:
miR (show MLXIP ELISA Kits)-1244 and MEF2D form an autoregulatory loop contributing to the progression of lung carcinoma.
MEF2D was also found to increase the transcription of Pokemon by binding myocyte enhancer factor 2 (MEF2) sites within its promoter region, that can promote Hepatocellular carcinoma invasion
Cell cycle progression was also inhibited by MEF2D suppression.
OA induced cell cycle arrest in lung cancer cells through miR (show MLXIP ELISA Kits)-122/Cyclin G1 (show CCNG1 ELISA Kits)/MEF2D pathway. This finding may contribute to the understanding of the molecular mechanism of OA's anti-tumor activity
MEF2C and MEF2D interact with the E3 ligase F-box protein SKP2, which mediates their subsequent degradation through the ubiquitin-proteasome system.
MEF2D suppression was shown to decrease the proliferation of osteosarcoma cells.
Oxidation of survival factor MEF2D inhibits its function, underlies oxidative stress-induced (show SQSTM1 ELISA Kits) neurotoxicity, and may be a part of the Parkinson disease pathogenic process.
The oncogenic properties of rhabdomyosarcoma cells can be partially attributed to the loss of MEF2D expression.
MEF2D-silencing abolished hepatocellular carcinoma tumorigenicity.
The expression of MEF2D was higher in the higher clinical stage of nasopharyngeal carcinoma, but there was no correlation with survival rate.
These findings uncover a novel role for Mef2c (show MEF2C ELISA Kits)/d in coordinating the transcriptional network that promotes early B-cell development.
This study identifies MEF2D as a critical regulator of IL-10 (show IL10 ELISA Kits) gene expression that negatively controls microglia inflammation response and prevents inflammation-mediated cytotoxicity.
Mef2d is essential for the maturation and integrity of retinal photoreceptor and bipolar cells
miR (show MLXIP ELISA Kits)-103 worked through activating AKT (show AKT1 ELISA Kits)/mTOR (show FRAP1 ELISA Kits) signal pathway and impairing target gene MEF2D.
These findings demonstrate that broadly expressed TFs acquire specific functions through competitive recruitment to enhancers by tissue-specific Mef2d and through selective activation of these enhancers to regulate tissue-specific genes.
Whereas MEF2A (show MEF2A ELISA Kits) is absolutely required for proper myoblast differentiation, MEF2B (show MEF2B ELISA Kits), -C, and -D were found to be dispensable for this process.
A role for endogenous MEF2 (show MEF2C ELISA Kits) factors exclusively in hormone/Fsk/cAMP-induced Nr4a1 (show NR4A1 ELISA Kits) gene expression in mouse MA-10 Leydig cells.
Results demonstrate that coordinated alternative splicing by a single RNA binding protein modulates transcription (Mef2d) and cell signaling (Rock2 (show ROCK2 ELISA Kits)) programs to drive tissue-specific functions (cell fusion) to promote a developmental transition.
We found that Parkinson's disease -associated neurotoxins destabilize MEF2D mRNA and reduce its level in vitro and in vivo.
Expression analysis showed that the MEF2D polymorphisms were highly correlated with MEF2D mRNA and protein levels in the longissimus dorsi muscle of Polish Holstein-Friesian bulls carrying the three different combined genotypes.
This gene is a member of the myocyte-specific enhancer factor 2 (MEF2) family of transcription factors. Members of this family are involved in control of muscle and neuronal cell differentiation and development, and are regulated by class II histone deacetylases. Fusions of the encoded protein with Deleted in Azoospermia-Associated Protein 1 (DAZAP1) due to a translocation have been found in an acute lymphoblastic leukemia cell line, suggesting a role in leukemogenesis. The encoded protein may also be involved in Parkinson disease and myotonic dystrophy. Alternative splicing results in multiple transcript variants.
myocyte enhancer factor 2D
, MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)
, myocyte-specific enhancer factor 2D-like
, MADS box transcription enhancer factor 2, polypeptide D
, myocyte-specific enhancer factor 2D